![]() UNITY is developing therapeutics to extend healthspan by slowing, halting or reversing diseases of aging. ![]() For more information, please visit About UNITY Ascentage has built a rich pipeline of eight clinical candidates, including a novel, highly potent Bcl-2/Bcl-xL inhibitor, APG-1252, as well as candidates aimed at IAP and MDM2-p53 pathways, and next-generation tyrosine kinase inhibitors. Based on breakthrough technology from the University of Michigan, the Company’s expertise is in designing therapeutics that inhibit protein-protein interactions to restore apoptosis, or programmed cell death, in cancers. “Their decision further validates our industry-leading expertise in the discovery and development of small molecules for complex and difficult-to-target protein-protein interactions including Bcl-2 and other apoptotic pathways.”Īscentage Pharma is a globally-focused, clinical-stage biopharmaceutical company developing novel small molecule therapies for cancers, hepatitis B and age-related diseases. Dajun Yang, Chairman & CEO of Ascentage Pharma. “We’re pleased that UNITY has chosen one of our compounds for IND-enabling studies focused on age-related diseases of the eye,” commented Dr. Under terms of the UBX1967 license agreement with UNITY, Ascentage is eligible to receive an upfront payment in shares of UNITY’s common stock and cash milestone payments and royalties based on clinical development and commercial sales milestones of UBX1967. The parties have now entered into a compound license agreement for the selected compound, UBX1967. The two companies previously entered into a compound library agreement giving UNITY access to certain small molecule inhibitors of Bcl-2 proteins, which not only have been implicated in the formation of various types of cancer but also in diseases of aging. (Nasdaq:UBX) has selected one of Ascentage’s compounds as its lead development candidate in its ophthalmology pipeline to advance into further preclinical studies to enable an Investigational New Drug (IND) application. ^ "Buzzy anti-aging biotech Unity drops leading program after flop, shares in freefall".Rockville, Maryland and Hong Kong-January 8, 2019-Ascentage Pharma, a global clinical-stage biopharmaceutical company dedicated to developing apoptosis-targeted therapies for cancers and other diseases, today announced that Unity Biotechnology, Inc.Announces Pricing of Initial Public Offering of Common Stock". ^ "Unity Biotechnology to focus on senolytic programs in ophthalmology, neurology".^ a b "Longevity Company Unity Biotechnology Stocks Soared After CEO Talks to CNBC | BioSpace"." 'Senolytic' Therapy Shows Promise in Neovascular Eye Disease". "Naturally occurring p16Ink4a-positive cells shorten healthy lifespan". "Boosting Life Span By Clearing Out Cellular Clutter". ^ Greenfieldboyce, Nell (3 February 2016).^ Scudellari, Megan (25 February 2017)."A biotech startup that aims to rid our bodies of cells related to aging just got a big investment". "Scientists Can Now Radically Expand the Lifespan of Mice-and Humans May Be Next". ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |